45
Participants
Start Date
December 31, 2008
Primary Completion Date
June 30, 2011
Study Completion Date
June 30, 2011
Plitidepsin and Sorafenib
Patients will receive i.v. plitidepsin over 1h on days 1, 8 and 15 every 4 weeks (d1, 8, 15 q4wk) and continuous oral sorafenib twice daily (bid) (a cycle is defined as an interval of 4 weeks).
Gemcitabine and Plitidepsin
Patients will receive i.v. gemcitabine over 30 minutes followed 1 hour later by plitidepsin over 1 hour on d1, 8, 15 q4wk (a cycle is defined as an interval of 4 weeks).
Institut Gustave Roussy, Villejuif
The Cancer Institute of New Jersey (CINJ), New Brunswick
Lead Sponsor
PharmaMar
INDUSTRY